Mehul Nagarsheth, MD
Glaucoma Specialist · Wyomissing, PANPI 1073774774
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 62.5% of it on its own, with 23 other manufacturers making up the rest.
Across 450 payments — averaging $70.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$20K
- AbbVie$4K
- Sight Sciences, Inc.$2K
- Alcon$2K
- NEW World Medical,inc.$1K
- Nova Eye, Inc.$1K
- plus $2K from 18 others
What the payments were for
- Consulting fees$17,33655%
- Speaking & faculty fees$1000%
- Travel & lodging$1,8216%
- Food & beverage$12,47139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 38 | $19,822 |
| AbbVie(2 entities) | 160 | $4,160 |
| Sight Sciences, Inc. | 71 | $1,917 |
| Alcon | 76 | $1,503 |
| NEW World Medical,inc. | 15 | $1,349 |
| Nova Eye, Inc. | 3 | $1,020 |
| Tarsus Pharmaceuticals, Inc. | 7 | $352 |
| Iridex Corporation | 4 | $286 |
| Bausch & Lomb Americas Inc. | 26 | $254 |
| Ivantis, Inc | 14 | $246 |
| Eyevance Pharmaceuticals LLC | 1 | $190 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $167 |
| Novartis | 5 | $69 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| Aerie Pharmaceuticals, Inc. | 3 | $48 |
| Rxsight Inc | 1 | $37 |
| Amgen | 2 | $35 |
| Thea Pharma Inc. | 2 | $34 |
| Akorn Operating Company LLC | 1 | $22 |
| Alcon Research LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Ocular Therapeutix, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDose$9,771
- Travoprost Intraocular Implant - iDose$1,950
- iStent infinite Trabecular Micro-Bypass System Model iS3$1,250
- Kahook Dual Blade$1,193
- Ahmed Glaucoma Valve$1,193
- Streamline Surgical System$981
- DURYSTA$930
- OMNI(R) SURGICAL SYSTEM (US)$283
- XEN GLAUCOMA TREATMENT SYSTEM$274
- Clearpath$212
- Streamline$212
- Via360$212
- Tobradex ST$190
- XDEMVY$150
- LUMIGAN$124
- iStent inject W$114
- KXL System$114
- Photrexa$114
- SION SURGICAL INSTRUMENT$105
- XEN$100
How this compares
Too few glaucoma specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 435 | $208,480 |
| CombiganBrimonidine Tartrate/Timolol | 256 | $86,028 |
| VyzultaLatanoprostene Bunod | 98 | $50,528 |
| RocklatanNetarsudil Mesylat/Latanoprost | 92 | $36,646 |
| Alphagan PBrimonidine Tartrate | 91 | $33,257 |
| RestasisCyclosporine | 28 | $27,692 |
| AzoptBrinzolamide | 46 | $26,546 |
| Prednisolone Acetate | 834 | $25,603 |
| RhopressaNetarsudil Mesylate | 57 | $24,658 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 74 | $22,993 |
| Latanoprost | 2,075 | $21,695 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 920 | $20,946 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 113 | $19,064 |
| Timolol Maleate | 557 | $14,239 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 79 | $13,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $4,160 | $355,457810 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $48 | $61,304149 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $254 | $50,52898 claims |
| AlconAzopt, Simbrinza | $1,503 | $49,539120 claims |
| Thea Pharma Inc.Iyuzeh | $34 | $7,70623 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $64 | $3,87222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Wyomissing
- Abhishek NemaniWyomissing$10K
- Michael SmithWyomissing$3K
- Ayan ChatterjeeKing Of Prussia$17K
- Alex TheventhiranPhiladelphia$4K
- Andrew WilliamsPittsburgh$4K
- Zachary NadlerAbington$4K
- Tadhg SchempfSewickley$3K
- Moon Jeong LeePhiladelphia$3K
- Shelley MoLancaster$3K
- Monica ZhangPhiladelphia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.